[December 19, 2014] |
|
Research and Markets: Hypercholesterolemia - Pipeline Review, H2 2014
Research and Markets (http://www.researchandmarkets.com/research/6zv47p/hypercholesterolem)
has announced the addition of the "Hypercholesterolemia
- Pipeline Review, H2 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Hypercholesterolemia, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Hypercholesterolemia and special features on late-stage and discontinued
projects.
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinicaltrials registries tracking ensure that the most recent
developments are captured on a real time basis.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Hypercholesterolemia
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Hypercholesterolemia pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Bristol-Myers Squibb Company
-
Johnson & Johnson
-
Amgen
-
Eli Lilly and Company
-
Merck & Co
-
Pfizer
-
Santaris Pharma
-
SoluBest
-
Alnylam Pharmaceuticals
-
Regeneron Pharmaceuticals
-
CrystalGenomics
-
Catabasis Pharmaceuticals
-
Planet Biotechnology
-
Zhejiang Hisun Pharmaceutical
-
Esperion Therapeutics
-
Progenra
-
Serometrix
-
Hanmi Pharmaceuticals
-
AtheroNova.
-
Immune Response BioPharma
-
Agilvax
-
Michigan Life Therapeutics
-
LondonPharma
-
Dybly
For more information, visit http://www.researchandmarkets.com/research/6zv47p/hypercholesterolem.
[ Back To TMCnet.com's Homepage ]
|